Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug
REUTERS
A new lawsuit claims Bristol-Myers Squibb Co (BMY.N) improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019. read more »